Clinical meaning
Gestational diabetes mellitus (GDM) is a carbohydrate intolerance of variable severity that is first recognized during pregnancy. The condition affects approximately 3-9% of all pregnancies and is one of the most common metabolic complications of the antepartum period. During normal pregnancy, the placenta produces hormones that are essential for fetal growth, including human placental lactogen (hPL), cortisol, estrogen, and progesterone. These hormones create a progressive state of insulin resistance that begins around 20-24 weeks of gestation and intensifies throughout the third trimester. Human placental lactogen is the primary diabetogenic hormone; it acts as an insulin antagonist by decreasing maternal glucose uptake at the cellular level, effectively diverting glucose across the placenta to the developing fetus. In a healthy pregnancy, the maternal pancreas compensates by increasing insulin production two to three times above normal baseline. However, when the maternal pancreatic beta cells cannot produce sufficient insulin to overcome the placental hormone-mediated insulin resistance, blood glucose levels rise and gestational diabetes develops. At the cellular level, insulin resistance in GDM involves impaired post-receptor signaling in the insulin receptor substrate pathway, specifically reduced phosphorylation of IRS-1, which decreases GLUT4 transporter translocation to the cell membrane surface. This means that even though insulin is present and binding to its receptor, glucose cannot efficiently enter maternal skeletal muscle and adipose tissue cells. The persistent hyperglycemia that results has significant consequences for both mother and fetus. Glucose crosses the placenta freely via facilitated diffusion through GLUT1 transporters, but insulin does not cross the placenta. When maternal blood glucose is elevated, excess glucose reaches the fetus, stimulating the fetal pancreas to produce large amounts of insulin (fetal hyperinsulinemia). Fetal hyperinsulinemia acts as a growth hormone, promoting excessive fat deposition and organ growth, resulting in fetal macrosomia (birth weight above 4000 grams or above the 90th percentile for gestational age). Macrosomia increases the risk of birth trauma including shoulder dystocia, brachial plexus injury (Erb palsy), clavicle fracture, and the need for operative delivery (cesarean section or instrumental vaginal delivery). After delivery, the neonate loses the maternal glucose supply but continues to produce high levels of insulin, placing the newborn at immediate risk for neonatal hypoglycemia within the first 1-2 hours of life. Other neonatal complications include polycythemia (increased red blood cell production due to chronic fetal hypoxia), hyperbilirubinemia (from polycythemia and immature liver), respiratory distress syndrome (hyperinsulinemia inhibits surfactant production), and hypocalcemia. For the mother, uncontrolled GDM increases the risk of preeclampsia, polyhydramnios (excess amniotic fluid from fetal polyuria), recurrent urinary tract infections, and cesarean delivery. Women with GDM have a 50-60% lifetime risk of developing type 2 diabetes mellitus, typically within 5-10 years postpartum, making long-term follow-up and lifestyle modification essential. The practical nurse plays a critical role in monitoring blood glucose levels, reinforcing dietary education, administering insulin as ordered, and recognizing signs of both maternal hyperglycemia and hypoglycemia during the antepartum and intrapartum periods.